From OHC

January 13, 2022

FOR IMMEDIATE RELEASE
Contact: Joanie Manzo
Director, Marketing & Physician Services
513-751-2145 x20143
joan.manzo@usoncology.com

According to the American Cancer Society, breast cancer is the most common cancer diagnosed among American women. “About two out of three breast cancers are estrogen receptor-positive (ER+),” noted OHC medical oncologist, Patrick J. Ward, MD, PhD. “Ongoing research is critical to develop new treatment strategies as these patients often face treatment resistance and recurrence of disease.” OHC recently announced the opening of a new breast cancer clinical trial evaluating a promising therapy for patients with this type of breast cancer. The research team is excited to bring this trial to patients in the region as OHC is the only practice in Ohio and one of 18 sites in the United States to offer this promising trial (https://clinicaltrials.gov/ct2/show/NCT04961996).

“This trial, LidERA, is the first adjuvant endocrine trial in quite some time,” said Dr. Ward, the principal investigator for the trial who also serves as Co-Director of OHC’s Research Department. Adjuvant therapies are those given after surgery to reduce the chance of disease recurrence. Specifically, this phase 3 study will evaluate the efficacy and safety of giredestrant compared to a physician’s choice of endocrine therapy in patients with ER+, HER2-negative early breast cancer.

Breast cancer is hormone receptor positive if its cells receive signals from the hormones estrogen or progesterone to grow. Estrogen encourages ER+ cancer cells to grow. Breast cancer is HER2 (human epidermal growth factor receptor 2)-negative if its cells have little or no HER2 protein.

“There is an unmet need for the treatment of ER+ breast cancer as some patients experience a recurrence of their breast cancer despite effective endocrine treatments,” said Dr. Ward. “It is thought that certain gene mutations, or changes, make some cancer cells more resistant to traditional treatments. Giredestrant is being developed to overcome this resistance. Data from previous trials reveal that giredestrant is a safe, tolerable treatment with robust anti-tumor activity.”

Giredestrant is an oral selective estrogen receptor degrader (SERD) that marks the estrogen receptor for destruction. It offers a more patient-friendly alternative to the current SERD that we use, Faslodex, which is the only one available in the United States. Faslodex is a large-volume intramuscular injection administered monthly. Oral giredestrant offers broader activity against the mutation that makes these cancer cells difficult to treat.

Through a steadfast commitment to research, and helping patients beat cancer, OHC’s cancer experts hope to find a cure for this devastating disease. The LidERA trial is currently enrolling patients at OHC. For more information on any of OHC’s clinical trials or to request a second opinion, call 1-888-649-4800 or visit ohcare.com.

OHC (Oncology Hematology Care) has been fighting cancer on the front lines for more than 35 years. We are the region’s leading experts in the treatment of nearly every form of adult cancer and complex blood disorder. OHC offers the latest medical, gynecologic and radiation therapy, and is always seeking better treatment options through its nationally recognized cancer research and clinical trials program. OHC is the first — and most experienced — independent adult cancer practice in the region to offer the ground-breaking CAR-T therapy for adults. OHC is certified by the American Society of Clinical Oncology in the Quality Oncology Practice Initiative Certification Program and is one of only a select few cancer practices nationally to be accepted to participate in the Oncology Care Model, part of The Center for Medicare & Medicaid Innovation. At its heart, our approach to cancer care is simple — to surround you with everything you need so you can focus on what matters most: beating cancer. For more information about OHC, or a second opinion, call 1-888-649-4800 or visit ohcare.com.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *